Effects of neomycin were studied on serum cholesterol and fecal steroids in hypercholesterolemic patients during a short treatment period (4 wk) and a long treatment period (16 mo), using small (1.5 g/d) and large (up to 6 g/d) doses alone and in combination with cholestyramine. In the short-term low-dose study the decrease in serum cholesterol by 21% was associated with a proportionate increase in fecal cholesterol elimination as neutral sterols through impaired cholesterol absorption. Serum cholesterol remained low and fecal steroid excretion remained elevated in the long-term neomycin study. Increasing the dosage from 1.5 to 6 g/d at the end of the 16-mo period brought about a further slight decrease in serum cholesterol and a small further increase in fecal neutral and acidic steroids. The increases in fecal bile acids and fat but not in neutral sterols were positively correlated with the increases in the neomycin dosage. Thus, large neomycin doses can also cause bile acid malabsorption. In another series of patients, a decrease (25%) in serum cholesterol by cholestyramine was associated with a proportional increase in the fecal elimination of cholesterol (2.5-fold) as bile acids. The inclusion of neomycin in cholestyramine therapy further increased fecal steroid output (solely as neutral sterols) by only about one-fifth of that due to cholestyramine, but further decreased serum cholesterol almost to the same 
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J. Clin (4) (5) (6) (7) (8) , its cholesterol-lowering effect was also assumed to be a result of enhanced bile acid excretion into feces, particularly because earlier studies, employing relatively large doses of neomycin or Nmethylated neomycin derivative without antibiotic properties, actually demonstrated an increase in both fecal bile acids and neutral sterols (6, 9, 10) . However, analysis of intestinal contents after administration of neomycin with a test meal revealed that the drug precipitated fatty acids and cholesterol, and only to a small extent bile acids from intraluminal micelles in man (11) . Small neomycin doses actually reduced serum cholesterol by enhancing cholesterol elimination into feces as neutral sterols, having no consistent effect on fecal bile acids (12, 13) . It is not, however, known whether large neomycin doses could also increase fecal bile acid output; whether the neomycin-induced increase in fecal steroids is long-standing, as the serum cholesterol lowering is; whether the decrease in serum cholesterol is related to changes in cholesterol tion, Inc. 0021-9738/79/11/1485/09 $1.00 elimination; and whether cholesterol synthesis is compensatorily increased by the drug. Cholesterol turnover studies off and on neomycin did not reveal any significant changes in the half time of the serum cholesterol radioactivity decay curve (14) , and the unchanged slope of this curve during the neomycininduced fall in serum cholesterol was interpreted to be a result of the combined action of reduced absorption, enhanced mobilization oftissue cholesterol and stimulated cholesterol synthesis (13) .
In the present study emphasis is placed on the effect of small and large neomycin doses on fecal steroids and serum cholesterol in short-and long-term treatment, and to neomycin-induced alterations in these parameters under conditions when cholesterol elimination is increased by cholestyramine in the form ofbile acids.
METHODS
Patients. The studies reported here were conducted on 17 subjects (Table I) in the metabolic ward. Most of the patients had a clear xanthomatotic, familial type II hypercholesterolemia and severe to moderate atheromatotic arterial disease. In patients 3, 7, 8, and 14 the family history was less clear, the degree of hypercholesterolemia was less severe and xanthomata were absent. Before the present investigation most of the patients had been on a low-cholesterol diet. Patient 8 had idiopathic hypercalciuria associated with enhanced intestinal calcium absorption and slight renal tubular insufficiency but normal plasma creatinine and creatinine clearance. There was no evidence of hyperparathyroidism. The purpose and design of the study were explained to the patients, and they agreed to act as volunteers. The protocol was approved by the ethics committee of the hospital.
Studies. The general plan of the study was first to record base-line values during a control period, then treat patients 1-8 with neomycin alone, and patients 9-17 with cholestyramine followed by a combination of cholestyramine and neomycin. For these purposes all the subjects were placed on a solid food low-cholesterol diet containing 80 g fat (a mixture of lard and soya oil)/2,400 kcal. Analysis of the diet revealed that the average cholesterol content was 120 mg/2,400 kcal. Chromic oxide (Cr203) and 8-sitosterol (200 mg of each three times a day) were given so that the respective corrections for fecal flow and any degradation of cholesterol during intestinal transit could be made (15) . After 7-10 d on the diet, Cr2O3 and 8-sitosterol 2-or 3-d stool collections were started. After one to three collections either neomycin (1.5 g/d) or cholestyramine (Cuemid; 32 g/d) therapy was started. Fecal collections were performed during the last few days of each treatment period. After 10-12 d of cholestyramine, neomycin was also given to patients 9-17 for an additional 10-12 d. In patients 2 and 5 fecal collection was performed during rehospitalization after the patients had been on neomycin for 4.5 and 1.5 mo, respectively. Patient 12 was first on cholestyramine for 35 d and then on combined cholestyramine-neomycin therapy for 12 d. Rehospitalization to obtain the control values ofthis case took place 2 mo later.
Even though maximal blood cholesterol reduction was achieved during the 1st wk on the drugs, any mobilization of tissue cholesterol may have continued so that sterol metabolism of the patients was still most likely in a nonsteady state at the end of each short-term treatment period. Thus, the sterol balance value, the difference between cholesterol intake and fecal excretion of acidic and neutral steroids of cholesterol origin obtained at the end of each short-term drug period, might have exceeded the actual cholesterol synthesis by an unknown amount of the cholesterol mobilized from tissues. Therefore, to eliminate any nonsteady state of the short-term experiments, sterol blalance studies were repeated after the patients had been on neomycin for 1 yr or more. Five subjects volunteered (patients 1, 4, 5, 10, and 13) to undergo long-term studies and were rehospitalized after they had been on neomycin for 390-660 d. Patients 10 and 13 had been oni comhined cholestv,raminie-nieom-cin treatment for 2 mo after the first stuidies but since then had been on neomycin alone. After the base-line reinvestigations had been performed, the neomycin dose was increased from 1.5 to 2 g in patient 10, to 3 g in patient 13, and to 6 g in patients 1, 4, and 5. Fecal collections were repeated at the end of the 10-to 14-d period on the large neomvcin dose.
Chemical analysis. Total serum cholesterol was determined by the method of Pearson et al. (16) from the petroleum ether extract of nonsaponifiable material. Triglycerides were measured according to Kessler and Lederer (17) . Fecal and acidic steroids were isolated separately and their masses were quantitated by the thin-layer chromatography-gas-liquid chromatography method as presented previously (18, 19) . This method permits a distinct separation between neutral sterols of cholesterol and plant sterol origin provided unchanged parent sterols are isolated fro)m the bacterial conversion products with thin-layer chromatography before gas-liquid chromatography quantitation-. Thin-layer chromatography purification is not necessary for bile acids (20 (Fig. 2 ).
Long-term effects of neomnycin. As shown in Table   II and Fig. 1 Table II ) from 1.5 to 2-3 g/d after long-term treatment had no further effect on serum cholesterol, but at a dose of 6 g/d an additional drop was recorded in the serum total cholesterol level of patients 4 and 5. The further mean reduction of the whole group was 9% and the overall fall 29%. The fall in cholesterol was significantly correlated with the neomycin dose (r = 0.690; P < 0.01; the differences from the control values at all neomycin doses were correlated with the respective neomycin doses shown in the footnote to Table II ). The increase in the neomycin dose was associated with slightly impaired fat absorption and with an increase in fecal steroid elimination (195 mg/d; 16%) that took place not only in the neutral steroid fraction but also in the acidic sterol fraction. The largest increase in fecal steroids was found on the highest dose in patients 4 and 5 in whom the fall in serum cholesterol was also largest. The correlation between the changes in serum cholesterol and fecal steroids did not quite reach a significant level, Neomycin Reduces Serum Cholesterol 1487 however (Fig. 2) . The plot ofthe changes in the neomy-to 1,497 mg/d, whereas fecal neutral steroids were not cin dose against the respective changes in fecal lipids consistently changed. Total cholesterol elimination revealed a positive correlation for bile acids and fecal was enhanced from 838 to 2,205 mg/d, the increase fat but not for neutral sterols (Fig. 3) .
being significantly correlated with the reduction in Effects of cholestyramine. Cholestyramine had no serum cholesterol (r = 0.850; P < 0.01). effect on serum triglycerides but it did decrease total Effects of neomycin in combination with cholescholesterol by 25% (Table III and Fig. 4) . This was tyramine. The administration of neomycin to patients associated with an increase in fecal bile acids from 203 on cholestyramine (Table III, Fig. 4) DAYS ON DRUGS FIGURE 4 Effects of cholestyramine and neomycin on serum lipids and fecal steroids. Relative changes (mean±SE) calculated from studies in Table III opposite side effects the patients found combination treatment convenient. The changes in serum cholesterol and fecal sterols were quantitatively similar whether neomycin was used alone or in combination with cholestyramine. Thus, the enhanced elimination of cholesterol as bile acid and subsequent increase in cholesterol synthesis caused by cholestyramine did not modify the mechanism by which neomycin lowers serum cholesterol. Enhanced cholesterol elimination as fecal neutral sterols because of impaired cholesterol absorption seems to be a primary phenomenon wherein small neomycin doses decrease the serum cholesterol level (12, 13) . This action is based on the disruption ofmicelles by neomycin in the intestinal lumen (11) . Comparative studies in vitro showed that neomycin precipitated sterols, phospholipids, and bile acids more effectively from the micellar phase of intestinal contents, obtained after a fat meal, than from the duodenal bile and that almost total sterol precipitation was obtained at fairly low neomycin additions (26) . Cholesterol is only absorbed in the upper small intestine, and micellar solubilization is obligatory for its absorption (27, 28) . Thus, once cholesterol is precipitated by neomycin it is hardly resolubilized in the sterol-absorbing area ofthe gut and is not absorbed. Accordingly, the increase in fecal neutral sterols resulting from administration of neomycin should equal that precipitated in the upper gut lumen. In view of the finding that the total daily flux of cholesterol into the gut lumen is usually 1 g or more (29) , the fecal increase was fairly small (m200 mg/d) (30) , and the reabsorption of conjugated bile acids is effective in the terminal ileum (31, 32) . If the precipitate were large, as it can be in the presence of high neomycin concentrations (26) , the absorption capacity would be exceeded, and increased amounts of fatty acids and bile acids would escape to the colon and feces. In fact, the change in neomycin dosage was correlated ( Fig. 2) (35, 36) . Because the drug effectively precipitates dihydroxy bile acids in vitro (8, 11, 26) , large neomycin doses would mostly increase fecal loss of chenodeoxycholate. Accordingly, the biliary bile acid composition should also be changed. In fact, 6 g/d appear to reduce the pool size of chenodeoxycholate (37) .
The leveling-off of serum cholesterol could be caused by (a) decrease in biliary secretion of cholesterol, (b) restoration of absorption, (c) increased tissue mobilization, and (d) enhanced synthesis. Though some change might have occurred in the first two conditions after the transition period, the persistant increase in neutral sterol elimination via reduced absorption and the data by Sedaghat et al. (13) indicate that intestinal flux is unchanged exclude these alternatives. The significant correlation found between the fall in serum cholesterol and the increase in fecal steroids indicated that a small fall in cholesterol is a result of a small increase in elimination and not of extensively increased synthesis and mobilization. On the other 1492 T. A. Miettinen hand, an extensive fall in cholesterol is caused by a greatly increased elimination and not by a negligible increase in synthesis and mobilization. Because the present subjects lost up to 190 g of cholesterol in the long-term neomycin treatment, it can be inferred that this could not be balanced solely by increased tissue mobilization but that synthesis is also increased. Earlier studies have shown a small decrease in the tissue cholesterol pool but no actual change in half times or courses ofthe decay curve of serum cholesterol specific activity (13, 14) . Neomycin alone or in combination with cholestyramine increased fecal steroid output by -250 mg/d, whereas cholestyramine caused an increase that was about five times higher. Thus, despite an almost equal decrease in serum cholesterol, the requirement for the compensatory increase in cholesterol synthesis caused by neomycin should be only about one-fifth that caused by cholestyramine. This suggests that stimulation of synthesis is mediated by different mechanism(s). Cholestyramine enhances the removal of cholesterol solely as bile acids and depletes hepatocyte cholesterol in man (24) , a change considered to be the major factor in stimulating hepatic cholesterol synthesis (38) . In addition, the drug may stimulate intestinal cholesterol synthesis to some extent in man (39) .
Inhibition of cholesterol absorption by neomycin, on the other hand, decreases the supply of absorbed cholesterol to the hepatocyte and should stimulate hepatic cholesterol synthesis (38) . However, in the rat neomycin actually had no effect on hepatic cholesterolgenesis but almost doubled intestinal cholesterol synthesis from acetate and increased conversion of mevalonate to nonsaponifiable lipids other than cholesterol (8) . The few analyses of intestinal biopsies' did not reveal any gross differences in the mucosal cholesterol, squalene, and methyl sterol concentrations, but the synthesis ofall these components was increased from both acetate and mevalonate in vitro during longterm neomycin treatment of hypercholesterolemic patients. Because the effective decrease in serum cholesterol by neomycin depends mainly on the sluggish increase in synthesis to balance cholesterol malabsorption, the mechanism and site of synthesis stimulation clearly need further exploration.
